Genentech, Breastcancer.Org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
October 02, 2026
October 02, 2026
SOUTH SAN FRANCISCO, California, Oct. 2 (TNSjou) -- Genentech, a member of the Roche Group, issued the following news release:
* * *
Genentech and Breastcancer.Org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
* More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer this year,/ . . .
* * *
Genentech and Breastcancer.Org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
* More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer this year,/ . . .